The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
15h
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis
Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...
Morning Overview on MSN
Researchers think they’ve found a path to restoring human vision
For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...
Sungkyunkwan University researchers in Korea ran a nationwide cohort analysis linking allergic diseases to increased optic neuritis risk, with allergic rhinitis showing the strongest association. A ...
A 71-year-old man was referred by his usual ophthalmologist to the neuro-ophthalmology clinic at Tufts Medical Center for bilateral decreased vision associated with bilateral optic disc edema. His ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback